ANI Pharmaceuticals Posts Record 2025 Revenue, Targets $1B in 2026
Event summary
- ANI Pharmaceuticals reported $247.1M in Q4 2025 revenue, up 29.6% YoY, with full-year revenue hitting $883.4M, a 43.8% increase.
- Rare Disease segment grew 84.1% YoY to $422.6M, driven by Cortrophin Gel's 75.6% YoY growth to $347.8M.
- Company reaffirmed 2026 guidance, targeting $1.05B–$1.11B in revenue, with Rare Disease expected to represent 60% of total revenue.
- Adjusted non-GAAP EBITDA rose 47.3% YoY to $229.8M, with Q4 EBITDA up 30.6% to $65.4M.
- ANI plans to expand its Rare Disease organization by ~90 people in mid-2026 to capture growth in acute gouty arthritis flares.
The big picture
ANI Pharmaceuticals is accelerating its transformation into a Rare Disease-focused company, leveraging the strong performance of Cortrophin Gel and ILUVIEN. The company's strategic pivot comes amid a broader industry trend of specialization in high-growth therapeutic areas. With $883.4M in 2025 revenue and a target of over $1B in 2026, ANI is positioning itself as a key player in the Rare Disease space, though it must navigate execution risks and potential regulatory challenges.
What we're watching
- Execution Risk
- Whether ANI can sustain its aggressive growth trajectory in Rare Disease, particularly with the planned expansion of its sales force for acute gouty arthritis flares.
- Market Dynamics
- How the company's shift toward Rare Disease will impact its Generics and Brands segments, which saw mixed performance in 2025.
- Regulatory Headwinds
- The potential impact of regulatory changes on ANI's ability to maintain profitability and commercialize its products at expected levels.
Related topics